MDxHealth Updates 2020 Reporting Calendar and Provides Initial View on Coronavirus Situation
IRVINE, CA, and HERSTAL, BELGIUM – April 1, 2020 – MDxHealth SA (Euronext: MDXH.BR), a commercial-stage innovative molecular diagnostics company, today updated its 2020 reporting calendar, moving its Q1 business update forward to April 9th from April 21st.
2020 Reporting Calendar
- April 9: Q1-2020 business update
- April 28: Online publication of annual report 2019
- May 28: Annual General Meeting
- August 26: Publication of H1-2020 results
- October 21: Q3-2020 business update
In the context of the novel coronavirus (COVID-19) pandemic, MDxHealth expects that the global measures taken to contain the virus may potentially impact the FY2020 outlook of the Company as published on February 26, 2020 with its FY2019 results. The Company is monitoring the situation closely and will provide more information in due course.
About MDxHealth
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary genetic, epigenetic (methylation) and other molecular technologies and assist physicians with the diagnosis of urologic cancers, prognosis of recurrence risk, and prediction of response to a specific therapy. The Company’s European headquarters are in Herstal, Belgium, with laboratory operations in Nijmegen, The Netherlands, and US headquarters and laboratory operations based in Irvine, California. For more information, visit and follow us on social media at: , and .
For more information:
| MDxHealth | |
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, and SelectMDx are trademarks or registered trademarks of MDxHealth SA.
Attachment
